Aim ImmunoTech Urges Shareholders To Vote On The White Universal Proxy Card "For" All 4 Incumbent Board Members; Believes Future Of The Co And That The Current Board Is Best Positioned To Continue Clinical Trial Momentum, Commercialize Ampligen And Deliver Long-Term Value For Shareholders

Believes Annual Meeting Outcome is Critical to Future of the Company and that the Current Board is Best Positioned to Continue Clinical Trial Momentum, Commercialize Ampligen and Deliver Long-Term Value for Shareholders

In AIM's View, the Activist Group's Plan to Reimburse Individuals More Than $5 Million for Failed Attempts to Gain Control of the Board – Without Putting this to a Shareholder Vote – Is Grossly Irresponsible and Not in the Best Interests of All Shareholders

Reminds Shareholders that Both Leading Independent Proxy Advisory Firms – ISS and Glass Lewis – Recommended Against Giving the Dissident Nominees Control of the AIM Board, Specifically Citing Their Lack of a Plan, Among Other Issues

Highlights Activist Group Nominees Todd A. Deutsch's and Robert L. Chioini's Checkered Pasts and Affiliations with Securities Law Criminals – and that Mr. Chioini Was Fired as CEO of Rockwell Medical for His "Sustained Mismanagement" and "Blatant Disregard for Shareholder Concerns"1

Questions How Activist Group Nominee Paul Sweeney Could Function as an Independent Director Given that Mr. Kellner is Apparently the Biggest Investor in Mr. Sweeney's Private Equity Firm

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024:

With the Annual Meeting quickly approaching, it is critical that shareholders vote on the WHITE universal proxy card to re-elect all four current members of our Board of Directors (the "Board"). As shareholders consider this important decision, we ask that they keep the following in mind: